Mon, 19 March 2018
Gavin Denton and I get together again to review a couple of recent papers that have some bearing on our practice. This month we cover Check Up- Position- "A Multicenter, Randomized Trial of Ramped Position vs Sniffing Position During Endotracheal Intubation of Critically Ill Adults" and the APRV trial -BILEVEL-APRV A Multicenter, Randomized Trial of Ramped Position versus Sniffing Position during Endotracheal Intubation of Critically Ill AdultsSemler et al, 2017.
Clinical question. In critically ill adults requiring endotracheal intubation, does the ramped position increase the lowest oxygen saturation during rapid sequence induction compared to the supine sniffing position.
Design.
Setting. Patients in critical care. Conducted in the United States of America.
Population.
Intervention/control.
Outcome.
Author’s conclusion. The ramped portion does not appear to improve oxygenation during intubation and may result in a worse glottic view and lower the first pass success.
Strengths.
Weaknesses.
Bottom line. This study did not demonstrate a benefit in oxygenation during RSI in the ramped position over the supine position and worsened glottic view and first pass success.
APRV trial -BILEVEL-APRV
In 2017 Zhou et al published a trial called “Early application of airway pressure release ventilation may reduce the duration of mechanical ventilation in acute respiratory distress syndrome.” In order to understand the trial and the results lets first be clear about what is APRV or Airway Pressure Release Ventilation and its basis on the principle of open lung ventilation. Open-lung ventilation refers to the concept of recruiting the lung and then ventilating gently with small tidal volumes, to avoid either over-distension or atelectotrauma (lung damage from cyclical opening/closing of alveoli).
Two levels of PEEP: high (P-high) and low (P-low) patient breaths spontaneously during P-high and P-low time in P-high (T-high) is longer than P-low (T-low) to maintain recruitment (85-95%) results in a degree of autoPEEP due to the short release time (T-low)
Advantages alveolar recruitment and improved oxygenation preservation of spontaneous breathing reduction of left ventricular transmural pressure and therefore reduction of left ventricular afterload potential lung-protective effect better ventilation of dependent areas lower sedation requirements to allow spontaneous breathing
Disadvantages risks of volutrauma from increased transpulmonary pressure increased work of breathing due to spontaneous breathing increased energy expenditure due to spontaneous breathing worsening of air leaks (bronchopleural fistula) Increased right ventricular afterload, worsening of pulmonary hypertension Reduction of right ventricular venous return: may worsen intracranial hypertension, may worsen cardiac output in hypovolemia Risk of dynamic hyperinflation
There have been animal studies demonstrating that APRV can increase alveolar recruitment gas exchange and therefore reducing lung injury. The ARDSnet trial established that mechanical ventilation at a six mls per kilo set tidal volume was superior to 12 mls per kilo in patients meeting criteria for ARDS. Several studies since have demonstrated that this target is often not adhered to.
The comment in Rob McSweeney’s review is that the use of APRV in patients with ARDS has been led by enthusiasm rather than rigorous evidence of benefit. As Jonny points out here, ARDS is an inflammatory process leading to increased lung vascular permeability which further leads on to hypoxaemia and reduced lung compliance. As a consequence we tend to ventilate this type of patient with low tidal volume ventilation.
The aim of this study therefore was to establish whether the use of APRV will reduce the duration of mechanical ventilation versus low tidal volume ventilation. So this was a single centre, randomised controlled trial comparing APRV against low tidal volume lung protective ventilation in patients with ARDS conducted in China. Eligible patients were having mechanical ventilation for greater than 48 hours and met the Berlin diagnostic criteria for ARDS. Amongst the exclusions were those with relative contraindications to APRV including those with barotrauma, severe chronic obstructive pulmonary disease and intracranial hypertension. You can see from Johnny’s info graphic the settings here in the intervention arm and the primary outcome to be measured was the number of ventilator free days up to date 28. Secondary endpoints included clinical outcomes (including mortality) and respiratory mechanics. Overall over 16 months 138 patients were enrolled. Raised intracranial pressure and unexpected early extubation were the commonest exclusion reasons. So patients in the APRV group had significantly more ventilator free days by day 28 than those in the low tidal volume group- p value 0.001 more patients receiving APRV were successfully extirpated and fewer required tracking ostomy. Neuromuscular blockade, prone positioning, nitric oxide or high frequency oscillators ventilation was required in 34% of patients in the low tidal ventilation arm and 8% of patients receiving APRV. Length of stay was significantly reduced in ICU but not in hospital stay. Intensive care unit mortality and hospital mortality were not significantly reduced with APRV. At day three patients receiving APRV had significantly lowerFiO2 and higher mean airway pressures and pAO2. Patients receiving APRV also had a lower mean heart rate and higher mean arterial pressure. Finally at day three and a seven APRV patients were less sedated by RASS scoring and receiving less sedatives by infusion.
Whilst these results also and very encouraging there are a number of problems with this study which should lead us to view the results with care. Firstly this was a single centre study with relatively small numbers which could mean that rare, but serious adverse events of either therapy may have been missed.
The trial was conducted in China which may lead to differences in both the patient population and the type of health care system to that found in the West. Due to the nature of the trial those treating the patients were unblinded to the treatment allocation which could raise a possible bias.
Tidal volumes of up to 8 mills per kilo were allowed in the low tidal volume ventilation group. This is higher than that recommended in the ARDSnet trial. The P low was also set to 5 cm whereas a P low of zero is more commonly advocated. So due to some of these issues and the fact that the results from this study are not in agreement with previous randomised studies, which have found in the past that APRV leads to increased time to extubation, and also having shown improved outcomes with low tidal volume ventilation in ARDS it is felt that repetition of this study in a large multicentre setting would be advisable.
Links Emcrit- https://emcrit.org/pulmcrit/aprv/ Life in the Fast Lane- https://lifeinthefastlane.com/ccc/airway-pressure-release-ventilation-aprv/
Interview Questions for Advanced Critical Care Practitioners
The Content on the website is provided for FREE as is the podcast. You could help support this work by going to Amazon via this link. This means that I will earn a small commission from any purchases you make with NO extra cost to yourself. Thank you. Amazon Link[table id=1 /] [Stitcher_Radio_Logo] [get_in_touch_with_jonathan]
|